证券代码：603858 证券简称：步长制药 公告编号：2025-131 山东步长制药股份有限公司 关于投资基金拟减资暨公司出资比例变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、交易概述 （一）基本情况 山东步长制药股份有限公司（以下简称"公司"）作为有限合伙人参与认购 投资的投资基金海南三亚御海成长股权投资基金合伙企业（有限合伙）（以下简 称"海南三亚御海"或"投资基金"）的有限合伙人绿叶投资集团有限公司（以 下简称"绿叶投资集团"）拟退伙。绿叶投资集团退伙、海南三亚御海减资完成 后，海南三亚御海的出资额将由 61,450 万元减少至 51,450 万元，公司认缴出资 额不变，出资比例将由 16.2734%变更为 19.4363%。 （二）审议情况 公司于 2025 年 7 月 8 日召开第五届董事会第二十七次会议，审议通过了《关 于投资基金拟减资暨公司出资比例变更的议案》，该事项无需提交股东会审议批 准。 授权公司董事长赵涛、总裁赵超办理本次减资的全部手续，包括但不限于签 署相关文件，提交政 ...

Group 1 - The company announced a reduction in the capital of the Tianjin Haihe Bohong New Materials Equity Investment Fund Partnership, which it participated in, resulting in a decrease of its subscribed capital from 29,700,000.00 RMB to 26,686,835.39 RMB, maintaining a 19.80% stake [1][2] - The reduction was approved during the fifth board meeting and the fifth supervisory board meeting held on May 27, 2025, and the fund has completed the necessary business registration changes [2] - The fund's total capital after the reduction is approximately 13,347,819.96 RMB, with the fund's management being handled by Bozheng Capital Investment Co., Ltd. and Tianjin Ruixing Investment Management Co., Ltd. [2]

Core Viewpoint - The company announces a reduction in its capital contribution to the Tianjin Haihe Bohong New Materials Equity Investment Fund, which constitutes a related party transaction, following the fund's exit from certain investments and the need for capital adjustment [1][2][4]. Summary by Sections Transaction Overview - The Tianjin Haihe Bohong Fund reduced its capital contribution from CNY 150 million to CNY 134.78 million after exiting investments in Shandong Kaisheng New Materials Co., Ltd. and Tianjin Jiurui Biotechnology Co., Ltd., receiving a total of CNY 15.218 million [1][4][8]. - The company holds a 19.80% stake in the Haihe Bohong Fund, which is managed by Tianjin Ruixing Investment Management Co., Ltd., a related party in which the company owns 40% [1][5]. Related Party Transaction - The reduction in capital does not constitute a major asset restructuring and is within the board's approval authority, thus not requiring a shareholder meeting [2][3]. - The company has previously approved a reduction in its capital contribution to the fund from CNY 99 million to CNY 29.7 million due to changes in the fund's circumstances [3][4]. Financial Data - The Haihe Bohong Fund's total assets were reported at CNY 301.58 million, with net assets of CNY 301.54 million, and a net profit of CNY 5.44 million for the last audited year [6][7]. - The fund's financial performance showed a significant loss in the previous year, indicating a need for capital restructuring [7]. Approval Process - The board of directors and the supervisory board unanimously approved the capital reduction and related party transaction, confirming compliance with legal and regulatory requirements [12][13]. - Independent directors also supported the transaction, stating it aligns with the fund's operational needs and does not harm shareholder interests [12][13].